Results
21
Companies with strong growth potential, backed by optimistic outlooks both from analysts and management.
21 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
ADOC | €6.05 | 6.7% | 20.8% | €91.0m | €6.30 | PS15x | E63.0% | n/a | Pharmaceuticals & Biotech | ||
ALOKW | €19.00 | -3.7% | -26.9% | €157.0m | €30.30 | PE20.8x | E30.8% | n/a | Capital Goods | ||
VU | €140.10 | -1.4% | 6.6% | €2.2b | €195.20 | PE27.9x | E24.3% | 0.2% | Tech | ||
FDE | €28.90 | 1.0% | -26.2% | €151.2m | €60.33 | PE19.2x | E31.9% | n/a | Energy | ||
OSE | €6.46 | -1.2% | 89.2% | €140.5m | €10.15 | PS63.1x | E5.9% | n/a | Pharmaceuticals & Biotech | ||
ALMUN | €0.51 | 9.5% | -82.9% | €4.5m | €1.30 | PB0.4x | E149.2% | n/a | Tech | ||
ALICA | €10.95 | 4.3% | -23.2% | €88.6m | €16.00 | PE16.1x | E26.2% | 1.8% | Tech | ||
ALCUR | €6.78 | 1.5% | 179.0% | €39.1m | €8.48 | PE21.7x | E27.5% | n/a | Capital Goods | ||
MEDCL | €15.94 | 9.2% | 151.0% | €463.2m | €20.70 | PS38.8x | E69.6% | n/a | Pharmaceuticals & Biotech | ||
ALSMA | €4.28 | 10.6% | 76.9% | €22.3m | €5.80 | PE21.1x | E35.2% | n/a | Healthcare | ||
S30 | €1.75 | 2.9% | -43.2% | €186.9m | €2.75 | PB1.7x | E101.6% | n/a | Software | ||
ALLIX | €8.04 | 1.5% | -25.7% | €52.3m | €13.50 | PS1.6x | E100.3% | n/a | Software | ||
CLA | €1.79 | -4.5% | 11.8% | €101.5m | €4.75 | PE-20.3x | E90.6% | n/a | Software | ||
ALECP | €0.35 | 1.7% | -33.5% | €43.1m | n/a | PE47.9x | E86.8% | 0% | Media | ||
ALCIS | €8.56 | 0.5% | -18.1% | €66.7m | €12.10 | PE20.9x | E56.5% | 1.9% | Commercial Services | ||
ATEME | €3.97 | 5.6% | -58.1% | €45.6m | €8.00 | PB1.2x | E96.4% | n/a | Tech | ||
ALHOP | €22.90 | 7.5% | 29.4% | €65.8m | €30.05 | PE14.4x | E21.6% | 2.8% | Media | ||
OVH | €5.81 | 6.0% | -38.9% | €1.1b | €8.61 | PS1.2x | E101.1% | n/a | Software | ||
LSS | €28.90 | 3.2% | 10.7% | €1.1b | €34.75 | PE32.7x | E28.6% | 1.2% | Software | ||
ALPAT | €14.60 | 7.4% | 18.7% | €16.1m | €11.50 | n/a | E92.7% | n/a | Pharmaceuticals & Biotech | ||
EXN | €23.15 | 1.1% | 21.6% | €2.1b | €24.50 | PE48.6x | E28.4% | 0% | Software |